Taiwan Biomaterial Co., Ltd.
TTPEX:664937.20
TWD
-0.05
(-0.13%)
ISIN
TW0006649007
Return %
Stock
S&P 500
1Y
-42.06
14.20
3Y
16.25
81.12
5Y
50.28
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Wen Hsiang Chang
- Full Time Employees
- 46
- Sector
- Electronic technology
- Industry
- Electronic equipment/Instruments
- Address
- No. 188, Shengyi Road Zhubei TP Taiwan 30261
- IPO Date
- Aug 29, 2017
- Website
- twbm.com.tw
- Similar Companies
- Business
- Taiwan Biomaterial Co., Ltd. specializes in the research, development, manufacture, and sale of high-end implantable medical devices and biomedical materials in Taiwan. Its core product portfolio includes Foamagen, a foamy dura substitute used in neurosurgery; stroke thrombus negative pressure removal catheter systems designed for suction and removal of cerebrovascular embolism blood clots; nickel-titanium guidewires for guiding cerebral vascular surgeries; as well as tissue repair and regeneration products aimed at treating early osteoarthritis. The company integrates advanced biomedical technologies with clinical insights to develop innovative surgical materials and interventional devices. Founded in 2010, Taiwan Biomaterial is headquartered in Zhubei City, Hsinchu County, Taiwan. In recent years, Taiwan Biomaterial has experienced significant growth, with a reported sales increase of over 32% in 2024 and a strong profitability turnaround in 2025. The company posted notable earnings growth with third quarter 2025 sales rising to TWD 72.78 million from TWD 27.49 million the previous year and net income reversing from a loss to a TWD 28.65 million profit. This financial improvement is underpinned by expanding adoption of its medical device offerings and ongoing research and development initiatives. Taiwan Biomaterial continues to collaborate closely with clinicians to identify unmet surgical needs and translate these into commercially viable products, enhancing its local market position. The company operates primarily within the medical equipment and healthcare supplies industry sectors, focusing on the Taiwanese market where it provides specialized medical devices for neurosurgery, stroke intervention, and orthopedic tissue repair. Its product development philosophy emphasizes a combination of translational research, clinical cooperation, and technological integration, supported by modern manufacturing capabilities sourced both domestically and internationally. Taiwan Biomaterial maintains a commitment to innovation and quality in implantable medical devices, positioning itself as a key player in Taiwan’s healthcare and medical device landscape. There have been no recent publicly disclosed transformative partnerships, acquisitions, or name changes reported in the last two years. The company’s stable growth trajectory and enhanced financial performance reflect its strategic focus on expanding product lines and market penetration in the specialized medical device sector.